Andere talen Revance Therapeutics, Inc.

Aandelen

RVNC

US7613301099

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,95 ^USD	+4,77%		+16,18%	-55,06%

26/04	AbbVie verhoogt jaarwinstverwachting door sterke verkoop Skyrizi	RE
12/04	Revance Therapeutics, Inc. presenteert nieuwe DAXXIFY-gegevens op de jaarlijkse bijeenkomst van de American Academy of Neurology 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04-05-2024
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	04-05-2024
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024	02/05
AbbVie raises annual profit forecast on strong Skyrizi sales	26/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	15/04
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	12/04
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	28/03
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	27/03
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	11/03
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	07/03
Revance Therapeutics Prices $100 Million Public Offering	04/03
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	04/03
Revance Announces Proposed Public Offering of Common Stock	04/03
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	28/02
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	28/02
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	28/02
Revance Therapeutics, Inc. Announces Executive Changes	28/02
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Revance Therapeutics, Inc.

Aandelen

RVNC

US7613301099

Andere talen

Filters